Kristen Yen - 17 Jul 2024 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Officer title: Senior Vice President, Clinical Operations
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Issuer symbol
SLNO
Transactions as of
17 Jul 2024
Net transactions value
$0
Form type
4
Filing time
19 Jul 2024, 09:02:47 UTC
Previous filing
03 Jul 2024
Next filing
07 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Award $0 +85,000 +400% $0.000000 106,252 17 Jul 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 25% of the RSUs subject to the award shall vest on August 1, 2024, 25% of the RSUs subject to the award shall vest on the date that the U.S. Food and Drug Administration (FDA) accepts the Company's New Drug Application (NDA) for DCCR, and 50% of the RSUs subject to the award shall vest on the date that the FDA approves the Company's NDA for DCCR (the NDA Approval Date), subject to the Reporting Person continuing as a service provider through each such date.
F2 Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Remarks:

Officer title: Senior Vice President, Clinical Operations